Logo

Everest Medicine’s Nefecon Receives NMPA Approval for the Treatment of Primary IgA Nephropathy

Share this
Everest Medicine

Everest Medicine’s Nefecon Receives NMPA Approval for the Treatment of Primary IgA Nephropathy

Shots:

  • The approval was supported by the results of P-III STUDY (NefIgArd) which showed that Nefecon's treatment impact on kidney function, proteinuria, and microhematuria was higher in the Chinese cohort than it was in the global data set.
  • The results of the study depicted that within the Chinese subgroup, the average absolute alteration in eGFR after 24mos. indicated a 66% decrease in the decline of kidney function vs 50% reduction in the loss of eGFR observed in the global dataset
  • Nefecon, a patented delayed-release oral formulation of budesonide, a corticosteroid known for its robust glucocorticoid effects and minimal mineralocorticoid activity. Additionally, this Approval results in a $5M milestone payment to Calliditas, to be recorded as Q4 revenue

Ref: PRNewswire | Image: Everest medicines

Related News:- Calliditas Therapeutics Reports the US Regulatory Update on Nefecon for the Treatment of IgA Nephropathy

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Kritika Jha

Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions